Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of human epidermal growth factor receptor 2 protein (HER2). It was first used with docetaxel and another HER2-targeting monoclonal antibody trastuzumab to treat metastatic HER2-positive breast cancer. Since then, its indications have been expanded to be used as both neoadjuvant therapy and adjuvant therapy for the treatment of HER2-positive breast cancer with a high risk of recurrence.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
Lab / Company